New Discovery Track for Startups and MSMEs with Financial Assistance upto ₹ 50 cr under PRIP Scheme announced

1. At a Glance

• The Department of Pharmaceuticals (DoP) has added a New Discovery track to the Promotion of Research and Innovation in Pharma & MedTech (PRIP) Scheme. It gives startups and MSMEs up to ₹50 crore per company, project or portfolio of projects to discover new drugs and therapies. [1]
• It targets a critical funding gap in early-stage novel drug discovery. It works as large-scale risk capital and brings institutional investors in at an earlier stage of drug development. [1]
• Why it matters for UPSC: it is part of India's shift from cost-based to innovation-based growth in pharma. That links to Atmanirbhar Bharat, the "pharmacy of the world" image, and the GS-III topics of S&T and industrial policy. [1][5]

2. Why in the News

• 30 Sep 2026: DoP announced the New Discovery track. The PRIP portal opened for applications under the second call. [1]
• On the same date, DoP reported that 41 projects had been approved for about ₹1,600 crore under the first call. Evaluation of the remaining Round 1 applications is still going on. [1]
• DoP had earlier announced the second call under the ₹5,000 crore PRIP Scheme in a separate release. [2]

3. Background & Evolution

• Rationale: move the Indian pharma-MedTech sector from cost-based to innovation-based growth by strengthening the country's research infrastructure. [5]
• Cabinet approval: outlay of ₹5,000 crore over 5 years (FY 2023-24 to FY 2027-28). [5]
• 17 Aug 2023: scheme notified in the Gazette. [5]
• Launch: Dr Mansukh Mandaviya launched the National Policy on R&D and Innovation in the Pharma-MedTech Sector together with the PRIP Scheme. [6]
• 29 Oct 2024: the PM laid the foundation stone of the Centre of Excellence for Phytopharmaceuticals at NIPER Guwahati. [7]
• First call for proposals: covered industry and startup projects worth about ₹11,000 crore. [3]
• 19 Nov 2025: first call closed with 710 research projects received from industry, startups and MSMEs. [4]
• 31 Jan 2026: ₹183.46 crore had been released to set up the seven CoEs. [4]
• 2026: second call announced; the New Discovery track was added on 30 Sep 2026. [2][1]

4. Core Static Facts

Tracks under the second call [1]

• The first-call guidelines put the Early Stage project cost at up to ₹9 cr (for ₹5 cr assistance) and the Later Stage project cost at up to ₹285 cr (for ₹100 cr assistance). [5]
• Key terms
• TRL (Technology Readiness Level): a scale of how mature a technology is, from basic research (TRL 1) upwards.
• NCE: New Chemical Entity.
• NBE: New Biological Entity.
• Phytopharmaceuticals: plant-derived drugs.
• Biosimilars: close copies of already-approved biologic drugs. [1]

5. Multi-Dimensional Analysis

Economic

• Public money that carries early risk (risk capital) is meant to "crowd in" private investment. The 25% institutional co-funding requirement tests whether the market is willing to back a project. [1]
• The target is about ₹11,000 crore of total R&D investment from a ₹5,000 crore outlay. [3]
• The aim is to move India's generics-heavy industry up the innovation value chain. [1]

Scientific / Technological

• Early-stage drug discovery (TRL 1–3) is the classic "valley of death": the gap between a lab result and a fundable product. The New Discovery track funds projects up to TRL 6, which is about the point where they can move towards clinical development. [1]
• Component A CoEs build research capacity in specific niches such as flow chemistry, NDDS and phytopharmaceuticals, and strengthen industry-academia links. [7]

Strategic

• More indigenous NCE/NBE assets feed a globally competitive drug pipeline. This reduces dependence on imported innovation and supports Atmanirbhar Bharat. [1][8]

Governance / Administrative

• Approvals follow a multi-stage appraisal. [4]
• Tools for applicants include an online portal, a Milestone Descriptor Catalogue, an Application Support Toolkit and FAQs. [1]
• Round 1 applicants have been told not to resubmit the same project. [1]
• Implementation bottleneck: 710 applications were received but only 41 approved so far, so evaluation is taking time. [4][1]

Social / Health

• A domestic pipeline of new medicines, including drugs for anti-microbial resistance (AMR) and anti-viral use through the CoE focus areas, supports public health security. [7]

6. Recent Developments (last 12–18 months)

• 19 Nov 2025: first call closed with 710 applications. [4]
• By 31 Jan 2026: ₹183.46 crore released for the 7 NIPER CoEs. [4]
• Feb 2026: PIB's Budget 2026-27 series featured "Transforming India into a Global Biopharma Hub". [8]
• 2026: second call under the ₹5,000 crore PRIP Scheme announced. [2]
• 30 Sep 2026: New Discovery track (up to ₹50 cr) announced, the portal went live, and 41 first-call projects were approved for about ₹1,600 crore. [1]

7. Prelims Hooks

• PRIP is implemented by the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, not the Ministry of Health or DBT. [1]
• PRIP outlay: ₹5,000 crore over FY 2023-24 to 2027-28. [5]
• PRIP was notified in the Gazette on 17 August 2023. [5]
• New Discovery track: up to ₹50 crore per company, project or portfolio. [1]
• New Discovery track requires at least 25% co-funding from bona fide institutional investors. [1]
• New Discovery eligibility: startups and MSMEs with NCE/NBE projects at TRL 1–3, supported up to TRL 6. [1]
• Early Stage track: up to ₹5 crore, supported up to TRL 5; no co-funding if project cost is ≤ ₹1 crore. [1]
• Later Stage track: up to ₹100 crore, capped at 35% of project cost; open to large industry as well. [1]
• The three priority areas of the second call are New Medicines, Complex Generics & Biosimilars, and Novel Medical Devices. [1]
• Component A funds CoEs at 7 NIPERs. [5]
• NIPERs are Institutes of National Importance. [7]
• The Centre of Excellence for Phytopharmaceuticals is at NIPER Guwahati; its foundation stone was laid on 29 Oct 2024. [7]
• First call: 710 applications received; 41 projects approved for about ₹1,600 crore. [4][1]
• Expected outcome: about 300 projects, about ₹11,000 crore of R&D investment. [3]

8. Why the Clock Is the Biggest Risk

• The scheme ends before most discovery projects can finish
• PRIP runs only from FY 2023-24 to FY 2027-28 [5].
• A New Discovery project starts at TRL 1–3 (a basic lab idea) and can be funded up to TRL 6 (ready to move towards testing in humans) [1].

• Tracks announced in September 2026 leave about 18 months of the original scheme period. That is short for work that normally needs several rounds of lab and animal testing.

• Parliament's committee has already raised this

• The Standing Committee on Chemicals and Fertilizers said the scheme's aims are good, but pointed out that it ends in 2027-28 [11].
• It asked DoP to use the full ₹5,000 crore and, if needed, to seek an extension [11].

• DoP replied that it has sought and received budget approval from the Department of Expenditure up to FY 2029-30 [11]. The aspirant should write "extended up to FY 2029-30" only with this source, because the Cabinet outlay still reads FY24–FY28 [5].

• Slow approvals use up the time that is left

• The first call closed on 19 Nov 2025 with 710 applications [4].
• By 30 Sep 2026, about ten months later, only 41 had been approved, and evaluation is still going on [1].
• Each month spent on appraisal is a month less for the research itself, because the end date does not move.

9. Where the First ₹1,600 Crore Seems to Have Gone

• The average approved project is large, not startup-sized
• 41 projects got about ₹1,600 crore [1]. That is roughly ₹39 crore per project on average (simple division).
• The Early Stage track, meant for startups and MSMEs, gives at most ₹5 crore per project [1].

• So the first-call money most likely went mainly to big Later Stage projects (up to ₹100 crore each, open to large industry) [1]. DoP has not published a track-wise split, so treat this as a reasoned estimate, not an official figure.

• Much of the money may go to safer products, not new drugs

• The second call's priority areas include Complex Generics & Biosimilars (copies of existing drugs) alongside New Medicines [1].
• Large firms already earn from generics. They will choose the lower-risk option when they can.

• This is probably why DoP created a separate New Discovery track open only to NCE/NBE projects (new chemical or biological molecules) [1]. Without it, truly new drugs would compete for the same money as copy products.

• The ₹11,000 crore figure is a hope, not money already raised

• It is the expected total R&D spending, including private money, from a ₹5,000 crore public outlay [3].
• Whether it happens depends on companies paying their share. For example, under Later Stage the government pays at most 35%, so the company must find the other 65% [1].

10. The Investor Rule: Safety Check or Barrier?

• The case for the 25% rule
• A startup must bring at least 25% of the money from bona fide institutional investors (for example venture capital funds) [1].

• If professional investors put in their own money, the government is less likely to fund a weak idea. It also means the startup already has backers for the next stage.

• The strongest objection: the investors may not be there

• India's total R&D spending (GERD — Gross Expenditure on R&D) is only 0.6–0.7% of GDP [10].
• Private firms pay only about 36% of it. In China, South Korea and the US, the private share is more than 70% [10].

• This means Indian private money for risky research is scarce. A rule that requires private money first can block exactly the early-stage startups the track wants to help.

• Why investors hold back at TRL 1–3

• At this stage most molecules fail, and a return may be ten or more years away.

• Investors prefer projects close to a sale or licensing deal. So the rule may favour the "least risky of the risky" projects, not the most original science.

• An honest verdict

• The objection is partly right: the rule will leave out some good science that has no investor behind it.
• But without the rule, ₹50 crore per company with no outside check would be a large public bet. The Early Stage track (₹5 crore, no co-funding up to ₹1 crore project cost) is still there for ideas too early for investors [1].
• The real test is how many New Discovery applications actually arrive with investor backing. DoP should publish this number.

11. The Gap After TRL 6 That PRIP Does Not Fill

• New Discovery funding stops just before the most expensive stage
• The track funds only up to TRL 6 [1]. After that come human clinical trials, which cost much more than lab work.
• A startup that reaches TRL 6 can then apply only to the Later Stage track, where the government pays at most 35% [1].

• A small company rarely has the other 65%. It may end up selling or licensing its molecule, often to a large or foreign firm, before it earns much from it.

• Research money and regulation are managed separately

• PRIP is run by DoP under the Ministry of Chemicals & Fertilizers [1]. Clinical trial approval comes under CDSCO and the New Drugs and Clinical Trials Rules, 2019, under the Health Ministry.

• If trial approvals are slow, a project funded quickly under PRIP can still wait at the next step. The 2023 R&D policy was meant to address this link, but the note's sources do not report any fixed timeline for PRIP-funded molecules [6].

• What should follow

• DoP should publish, for each track, how many projects move to the next TRL level each year. This is better than reporting only rupees approved.
• DoP, following the Standing Committee's advice to use the full outlay [11], should give New Discovery projects that reach TRL 6 a priority slot in the Later Stage track, so they are not lost to lack of funds.

12. Anchors for Answers

• Data: India's GERD is 0.6–0.7% of GDP; private sector pays only about 36% of it, compared with more than 70% in China, South Korea and the US [10]
• Data: 710 first-call applications [4], but only 41 approved (about ₹1,600 crore) by 30 Sep 2026 [1]
• Report/Committee: Standing Committee on Chemicals and Fertilizers (18th Lok Sabha, 2025-26) — asked for full use of the ₹5,000 crore and an extension beyond 2027-28 [11]
• Law/Case: PRIP Gazette notification, 17 Aug 2023 [5]; New Drugs and Clinical Trials Rules, 2019 (the rules for the stage after TRL 6)
• Scheme: PLI for Pharmaceuticals — pays for manufacturing, while PRIP pays for R&D; together they aim to take India from making generics to making new drugs [9]

13. Mains Relevance

• GS-III: Science & Technology (developments and their applications; indigenisation of technology); Indian economy (industrial policy; mobilisation of resources; investment models).
• GS-II: Health, meaning government policies and interventions in the health sector.
• Possible questions 1. "India is the 'pharmacy of the world' but not yet its laboratory." Examine how schemes such as PRIP try to move the pharmaceutical sector from cost-based to innovation-based growth. 2. Discuss the 'valley of death' in early-stage drug discovery in India. How far can public risk capital that requires institutional co-investment close this gap? 3. Critically evaluate the role of NIPER Centres of Excellence and industry-academia linkages in building India's pharma-MedTech R&D ecosystem.

14. Related Topics to Study Next

• PLI Scheme for Pharmaceuticals / Bulk Drugs / Medical Devices: PRIP supports R&D, while PLI supports manufacturing. [9]
• National Policy on R&D and Innovation in Pharma-MedTech: the policy framework launched alongside PRIP. [6]
• NIPERs: Institutes of National Importance under DoP that host the Component A CoEs. [7]
• Anusandhan National Research Foundation (ANRF) and the RDI Fund: the wider public R&D financing architecture.
• BioE3 Policy / Biotech-KISAN / BIRAC (DBT): parallel support for biotech startups.
• New Drugs and Clinical Trials Rules, 2019 / CDSCO: regulation governs the path after TRL 6.
• Antimicrobial resistance (WHO GLASS, NAP-AMR): one of the CoE focus areas (anti-bacterial drug discovery).
• Phytopharmaceuticals and the Traditional Knowledge Digital Library (TKDL): plant-based drug discovery and protection of traditional knowledge.

15. Common Errors / Trap Areas

• Ministry: DoP sits under the Ministry of Chemicals & Fertilizers, not the Ministry of Health & Family Welfare or the Ministry of Science & Technology. [1]
• TRL ceilings: Early Stage goes up to TRL 5, New Discovery up to TRL 6. Both start at TRL 1–3. [1]
• Co-funding source: in New Discovery, the 25% must come from institutional investors, not the applicant's own funds. In Later Stage, the government share is capped at 35%. [1]
• ₹5,000 crore vs ₹11,000 crore: ₹5,000 crore is the government outlay; ₹11,000 crore is the expected total R&D investment. [3]
• Who is eligible: New Discovery and Early Stage are for startups and MSMEs only. Large industry can apply only under Later Stage. New Discovery is limited to NCE/NBE projects, not devices or generics. [1]